Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nigel S Key

Showing results (191-200 of 255) with videos related to

Pageof 26
Sort By:
Shock (Augusta, Ga.)|February 3, 2021
Neutrophil Extracellular Trap Formation and Syndecan-1 Shedding Are Increased After TraumaJulie Goswami, Taleen MacArthur, Kent Bailey, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 10, 2004
Andrographolide attenuates inflammation by inhibition of NF-kappa B activation through covalent modification of reduced cysteine 62 of p50Yi-Feng Xia, Bu-Qing Ye, Yi-Dan Li, et al.
Molecular Therapy. Methods & Clinical Development|September 19, 2025
Natural history of preexisting AAV5 antibodies in adults with hemophilia B during the lead-in of the etranacogene dezaparvovec phase 3 studyRobert Klamroth, Michael Recht, Nigel S Key, et al.
Kidney International Reports|April 30, 2025
Erratum to "Anticoagulation for the Prevention of Thrombotic Events in Nephrotic Syndrome" [<i>Kidney International Reports</i> Volume 9, Issue 10, October 2024, Pages 3053-3056]David Massicotte-Azarniouch, Daniel J Crona, Priscilla Karnabi, et al.
Nature Chemical Biology|February 25, 2014
Homogeneous low-molecular-weight heparins with reversible anticoagulant activityYongmei Xu, Chao Cai, Kasemsiri Chandarajoti, et al.
Kidney International Reports|October 21, 2024
Anticoagulation for the Prevention of Thrombotic Events in Nephrotic SyndromeDavid Massicotte Azarniouch, Daniel J Crona, Priscilla Karnabi, et al.
The New England Journal of Medicine|December 8, 2025
Final Analysis of a Study of Etranacogene Dezaparvovec for Hemophilia BSteven W Pipe, Wolfgang Miesbach, Michael Recht, et al.
Cancer Research|August 17, 2016
Thrombosis in Cancer: Research Priorities Identified by a National Cancer Institute/National Heart, Lung, and Blood Institute Strategic Working GroupNigel S Key, Alok A Khorana, Nigel Mackman, et al.
Blood Advances|April 6, 2025
Completion of Phase 2b trial of etranacogene dezaparvovec gene therapy in patients with hemophilia B over 5 yearsAnnette von Drygalski, Esteban Gomez, Adam Giermasz, et al.
Journal of the American Society of Nephrology : JASN|January 25, 2014
Sickle trait in African-American hemodialysis patients and higher erythropoiesis-stimulating agent doseVimal K Derebail, Eduardo K Lacson, Abhijit V Kshirsagar, et al.
Pageof 26

Showing results (191-200 of 255) with videos related to

Sort By:
Pageof 26
Shock (Augusta, Ga.)|February 3, 2021
Neutrophil Extracellular Trap Formation and Syndecan-1 Shedding Are Increased After TraumaJulie Goswami, Taleen MacArthur, Kent Bailey, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 10, 2004
Andrographolide attenuates inflammation by inhibition of NF-kappa B activation through covalent modification of reduced cysteine 62 of p50Yi-Feng Xia, Bu-Qing Ye, Yi-Dan Li, et al.
Molecular Therapy. Methods & Clinical Development|September 19, 2025
Natural history of preexisting AAV5 antibodies in adults with hemophilia B during the lead-in of the etranacogene dezaparvovec phase 3 studyRobert Klamroth, Michael Recht, Nigel S Key, et al.
Kidney International Reports|April 30, 2025
Erratum to "Anticoagulation for the Prevention of Thrombotic Events in Nephrotic Syndrome" [<i>Kidney International Reports</i> Volume 9, Issue 10, October 2024, Pages 3053-3056]David Massicotte-Azarniouch, Daniel J Crona, Priscilla Karnabi, et al.
Nature Chemical Biology|February 25, 2014
Homogeneous low-molecular-weight heparins with reversible anticoagulant activityYongmei Xu, Chao Cai, Kasemsiri Chandarajoti, et al.
Kidney International Reports|October 21, 2024
Anticoagulation for the Prevention of Thrombotic Events in Nephrotic SyndromeDavid Massicotte Azarniouch, Daniel J Crona, Priscilla Karnabi, et al.
The New England Journal of Medicine|December 8, 2025
Final Analysis of a Study of Etranacogene Dezaparvovec for Hemophilia BSteven W Pipe, Wolfgang Miesbach, Michael Recht, et al.
Cancer Research|August 17, 2016
Thrombosis in Cancer: Research Priorities Identified by a National Cancer Institute/National Heart, Lung, and Blood Institute Strategic Working GroupNigel S Key, Alok A Khorana, Nigel Mackman, et al.
Blood Advances|April 6, 2025
Completion of Phase 2b trial of etranacogene dezaparvovec gene therapy in patients with hemophilia B over 5 yearsAnnette von Drygalski, Esteban Gomez, Adam Giermasz, et al.
Journal of the American Society of Nephrology : JASN|January 25, 2014
Sickle trait in African-American hemodialysis patients and higher erythropoiesis-stimulating agent doseVimal K Derebail, Eduardo K Lacson, Abhijit V Kshirsagar, et al.
Pageof 26